Handbook on Injectable Drugs

“Try before you buy" - Download the FREE App, which includes sample content. In-App purchase required to unlock all content.

For over 50 years American Society of Health-System Pharmacists is the most comprehensive reference on injectable drug data. 2024 edition features 400+ monographs on parenteral drugs, 24,500+ compatibility pairs, 3,700+ unique references

5-Star Rating from Doody's Review Service and Doody's Core Titles List Selection
ASHP® Injectable Drug Information™ 2024 content is interactive, mobile, and updated quarterly. Includes monographs to Extended Stability for Parenteral Drugs, forming a single, comprehensive resource on injectable drug information..

Key Features
* Quick data search for 358 drugs
* 417 monographs on parenteral drugs available in the United States and in other countries
* Monographs cross-referenced with American Society of Health-System Pharmacists (AHFS) Drug Information through AHFS classification numbers
* More than 500 revisions to existing monographs (affecting 60% of the existing monographs) have been accomplished to update information on stability, compatibility, and safety (e.g., Food and Drug Administration [FDA] MedWatch alerts) and to provide more specific referencing of manufacturer information and enhancements to the more than 24,100 compatibility pairs contained in ASHP® Injectable Drug Information™ 2024.
* How to prepare, store and administer drugs
* Info accumulated from 3,603 references
* Drugs listed alphabetically by generic name for efficient searching, with brand names listed

WHAT'S NEW
ASHP® Injectable Drug Information™ 2024 includes
* 18 new monographs, bringing the total in this edition to 417 monographs on parenteral drugs available in the United States and in other countries.
* More than 500 revisions to existing monographs (affecting nearly 60% of the existing monographs) have been accomplished to update information on stability, compatibility, and safety (e.g., Food and Drug Administration [FDA] MedWatch alerts) and to provide more specific referencing of manufacturer information and other enhancements to the more than 24,100 compatibility pairs
* The information cited throughout the text has been compiled from 3603 references, including 195 new to this edition. Because information from pharmaceutical manufacturers had not been uniquely cited until the 18th edition, the number of unique references supporting ASHP® Injectable Drug Information™ 2024 information actually greatly exceeds this number.
* While primary, peer-reviewed literature remains a major source of compatibility and stability information, ongoing efforts are underway to provide increased specificity of references to the pharmaceutics research of drug manufacturers. Other relevant information and pertinent study details supplied by corresponding authors of the published literature also have been incorporated when available.
Content licensed from printed edition ISBN 10: 1585286834
Content licensed from printed edition ISBN 13: 9781585286836
SUBSCRIPTION :
Please purchase a yearly auto-renewing subscription to receive content access and available updates.

Yearly auto-renewing payments- $49.99

Payment will be charged to your iTunes Account at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user and auto-renewal can be disabled at any time by going to your device “Settings” and tapping “iTunes & App Store”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable.

If you have any questions or comments, email us any time: customersupport@skyscape.com or call 508-299-30000

Privacy Policy - https://www.skyscape.com/terms-of-service/privacypolicy.aspx
Terms and Conditions - https://www.skyscape.com/terms-of-service/licenseagreement.aspx

Editor(s): ASHP
Publisher: American Society of Health-System Pharmacists

更新履歴
* 18 new monographs, bringing the total in this edition to 417 monographs on parenteral drugs available in the United States and in other countries.
* More than 500 revisions to existing monographs (affecting nearly 60% of the existing monographs) have been accomplished to update information on stability, compatibility, and safety (e.g., Food and Drug Administration [FDA] MedWatch alerts) and to provide more specific referencing of manufacturer information and other enhancements to the more than 24,100 compatibility pairs
* The information cited throughout the text has been compiled from 3603 references, including 195 new to this edition. Because information from pharmaceutical manufacturers had not been uniquely cited until the 18th edition, the number of unique references supporting ASHP® Injectable Drug Information™ 2024 information actually greatly exceeds this number.
* While primary, peer-reviewed literature remains a major source of compatibility and stability information, ongoing efforts are underway to provide increased specificity of references to the pharmaceutics research of drug manufacturers. Other relevant information and pertinent study details supplied by corresponding authors of the published literature also have been incorporated when available.